Long-term toxicity and survival outcomes after stereotactic ablative radiotherapy for patients with centrally located thoracic tumors
, , , , , , und
26. Juni 2020
Über diesen Artikel
Artikel-Kategorie: Research Article
Online veröffentlicht: 26. Juni 2020
Seitenbereich: 480 - 487
Eingereicht: 02. Apr. 2020
Akzeptiert: 30. Mai 2020
DOI: https://doi.org/10.2478/raon-2020-0039
Schlüsselwörter
© 2020 Banu Atalar, Teuta Zoto Mustafayev, Terence T. Sio, Bilgehan Sahin, Gorkem Gungor, Gokhan Aydın, Bulent Yapici, Enis Ozyar, published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
Figure 1
Figure 2
Figure 3
Figure 4
Patient, tumor, and treatment characteristics for 65 patients (70 tumors) receiving stereotactic ablative radiotherapy (SABR)
| Characteristic | Value Values are median (range) or No. of patients/tumors (%). |
|---|---|
| Age, year | 64 (22 |
| Men | 50 (77) |
| Primary cancer | |
| Lung | 49 (70) |
| Colorectal | 10 (14) |
| Other (breast, gastric, melanoma, germ cell, RCC) | 11 (16) |
| Treatment indication | |
| Primary lung (medically inoperable T1–T2) | 12 (17) |
| Relapse (primary lung and oligometastatic) | 24 (34) |
| Oligometastatic | 34 (49) |
| Previous radiation to chest | 20 (29) |
| Tumor location | |
| ≤ 1 cm from tracheobronchial tree | 24 (34) |
| > 1 cm but ≤ 2 cm from tracheobronchial tree | 12 (17) |
| Lesions intersecting mediastinum | 22 (31) |
| ≤ 1 cm from thoracic aorta | 12 (17) |
| Left laterality | 37 (53) |
| Lesion size (PTV), cc | 33.4 (7.3–461.5) |
| Total dose, Gy | 55 (30–60) |
| Dose per fraction, Gy | 9.75 (4–18) |
| Fractions | 5 (3–10) |
| BED10, Gy | 110 (48–151.2) |
| BED10 | |
| < 100 Gy | 16 (23) |
| ≥ 100 Gy | 54 (77) |
| BED3, Gy | 228 (90–378) |
| Treatment time, days | 10 (5–19) |
| Treatment time | |
| < 10 days | 30 (43) |
| ≥ 10 days | 40 (57) |
| Treatment on consecutive days | 6 (9) |
Tumor and patient outcomes after stereotactic ablative radiotherapy (SABR) for central lung tumors
| Characteristic | Value Values are No. patients/tumors (%) or No. patients unless otherwise stated. |
|---|---|
| Response on 3-month PET/CT after SABR | |
| Complete response | 43 (61) |
| Partial response | 19 (27) |
| Progression | 2 (3) |
| Unknown (patient died before 3 months or imaging not performed) | 6 (9) |
| Locoregional control | |
| 2-year | 84% |
| 5-year | 70% |
| Median | Not reached |
| Overall survival | |
| 2-year | 52% |
| 5-year | 28% |
| Median | 28 months |
| 2-Year toxicity-free survival | 81% |
| All Toxicities (grade 2 or higher) | 17 (26.2%) |
| RT-induced pneumonitis | 9 (13.8%) |
| Brachial and recurrent laryngeal nerve injury | 3 (4.6%) |
| Esophagitis | 2 (3%) |
| Tracheal perforation | 1 (1.5%) |
| Fatal hemoptysis | 1 (1.5%) |
| Possible RT-related death | 1 (1.5%) |
| Toxicity, grade 5 (fatal) | 5 (7.7%) |
| RT-induced pneumonitis | 2 (3%) |
| Tracheal perforation | 1 (1.5%) |
| Fatal hemoptysis | 1 (1.5%) |
| Possible RT-related death | 1 (1.5%) |